Pharmafile Logo
Pharmafocus logo
Advanced Search

muscular dystrophy

Showing 6 posts of 6 posts found.

Santhera announces Early Access Program by partner Sperogenix for DMD treatment

June 11, 2024
Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera

Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …

News

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

May 14, 2024
Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …

News
7359dba7-e1da-4eb4-8765-58da6178899b

Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E

October 7, 2019
Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta

Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …

News
lab

Shares at Sarepta Therapeutics jump after FDA delay in drug approval review

May 26, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment

Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …

News
DMD

The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?

January 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs

The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …

Feature

Prosensa and GSK add to muscular dystrophy alliance

June 23, 2010
Research and Development GlaxoSmithKline, Prosensa, muscular dystrophy

GSK has extended its research alliance with biotech company Prosensa in the field of muscular dystrophy. Netherlands-based Prosensa focuses on …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026